Early acute cellular rejection: no effect on late hepatic allograft function in man.
Whereas early acute cellular rejection, even if successfully treated, seems to have an impact on late function and survival of kidney and heart transplants, little quantitative data are available on its effect(s) on liver transplants. Routine liver function tests, the functioning liver cell mass (galactose elimination capacity) and microsomal metabolic capacity (aminopyrine breath test) were determined prospectively in 37 consecutive patients 1 year after liver transplantation. Of these, 19 (7 females and 12 males, 32-69 years of age) had previously required treatment for at least one biopsy proven acute cellular rejection episode occuring a median 7 days after grafting, while 18 (6 females and 12 males, 30-67 years of age) had not. The functioning liver cell mass and microsomal metabolic capacity were both within normal limits for the majority of patients and did not differ significantly between patients with and without previous acute cellular rejection episodes. In contrast to other solid organ transplants, early acute cellular rejection episodes do not affect late function of liver allografts in man.
Seiler
C A
CA
Department of Visceral and Transplantation Surgery, University of Berne, Inselspital, Switzerland.
Renner
E L
EL
Czerniak
A
A
Didonna
D
D
Büchler
M W
MW
Reichen
J
J
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000632:Aminopyrine / Q000032:analysis; D001663:Bilirubin / Q000097:blood; D001944:Breath Tests; D005260:Female; D005690:Galactose / Q000378:metabolism; D006084:Graft Rejection / Q000503:physiopathology*; D006801:Humans; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D000632:Aminopyrine; D001663:Bilirubin; D005690:Galactose